How common is low testosterone, and why are rates rising in younger men?

Clinically documented symptomatic hypogonadism affects about 2.1% to 5.7% of men aged 40 to 79, but the true burden is likely higher because diagnosis requires persistent symptoms plus repeated low morning testosterone, commonly evaluated against thresholds such as 350 ng/dL for total testosterone and 100 pg/mL for free testosterone in symptomatic men. Rates appear to be rising in younger men for two reasons at once. More men are being tested, and the underlying drivers of testosterone decline now begin earlier in life.

Key takeaways

• Published estimates place symptomatic hypogonadism in men aged 40 to 79 at roughly 2.1% to 5.7%, with an incidence around 11.7 to 12.3 new cases per 1,000 people per year, but those figures likely undercount because most studies require symptoms plus two low morning testosterone results.^{[1] [2]}
• Healthy aging causes only a modest testosterone decline, while obesity, comorbidity, and weight gain have a much larger effect on testosterone levels dropping over time.^{[4] [5]}
• Age matched men from later U.S. birth cohorts had lower testosterone than men of the same age from earlier cohorts, supporting a real generational testosterone decline beyond simple aging.^[3]
• Low testosterone is especially common in men with obesity, type 2 diabetes, metabolic syndrome, cardiovascular disease, COPD, renal disease, and cancer, which means many hypogonadism statistics reflect interconnected disease rather than isolated hormone failure.^{[1] [6]}
• A low number alone is not a diagnosis. Male hypogonadism requires persistent symptoms plus biochemical evidence, and LH with FSH must be measured to classify primary versus secondary disease.^[1]
• In symptomatic men, decision making often centers on total testosterone around 350 ng/dL and free testosterone around 100 pg/mL, with morning testing between 07:00 and 11:00 using accurate methods.^[1]

How common is low testosterone really

Published estimates suggest symptomatic male hypogonadism affects about 2.1% to 5.7% of men aged 40 to 79, with an incidence around 11.7 to 12.3 cases per 1,000 person years.^{[1] [2]}

Prevalence means the proportion of men who meet diagnostic criteria at a given time. Incidence means the rate of new cases appearing over time.

According to the European Association of Urology guidance, those are the headline hypogonadism statistics clinicians should know, but they are best understood as minimum estimates rather than a final count.^[1] A 2010 New England Journal of Medicine study found a prevalence of about 2.1% when strict criteria were used, including sexual symptoms and repeatedly low testosterone.^[2] Other studies report higher numbers when broader symptom sets or different thresholds are used, which is why published prevalence spans a range rather than a single fixed value.

This matters because low testosterone prevalence is often misunderstood in two opposite directions. Some men assume the condition is extremely common because symptoms such as fatigue, weight gain, and lower libido are common. Others assume it is rare because relatively few men carry a formal diagnosis. Both impressions miss the clinical reality. Male hypogonadism is a syndrome, not a screening label. A man needs persistent symptoms and biochemical evidence of testosterone deficiency. A low number alone is not enough, and symptoms alone are not enough either.^[1]

That diagnostic strictness makes published rates conservative. Most prevalence studies require two separate low morning measurements, symptom confirmation, and exclusion of temporary illness related suppression. Most men in the community never undergo that full process. For a deeper explanation of why the syndrome is defined this way, see What is low testosterone? The clinical definition most men (and many doctors) get wrong.

Why published rates undercount

Most published hypogonadism statistics are lower than the real world burden because testing is selective, criteria are strict, and many symptomatic men are never evaluated at all.^{[1] [2]}

In practice, many men with testosterone declining over time do not present until symptoms become disruptive. Others are tested once, at the wrong time of day, or without the rest of the hormonal panel. Some are told their testosterone is “normal” because it falls inside a broad adult reference range even when symptoms persist and free testosterone may be low. Others are never tested because sexual symptoms are stigmatized, or because fatigue and weight gain are attributed to stress, work, or aging.

That is why low testosterone prevalence and hypogonadism statistics should be read as the number of men who were identified under strict research conditions, not the number of men actually affected.

Which groups carry the highest burden

Low testosterone is disproportionately common in men with obesity, type 2 diabetes, metabolic syndrome, cardiovascular disease, COPD, renal disease, and cancer.^{[1] [6]}

Comorbidity means a disease that exists alongside another disease. In hypogonadism, comorbidity is not just background noise. It often helps cause the hormonal problem, and the hormonal problem can then worsen the comorbidity.

Obesity, diabetes, and metabolic syndrome

Obesity, type 2 diabetes, and metabolic syndrome form the most important cluster behind low testosterone prevalence in routine clinical practice.^{[1] [6]}

According to the EAU guideline, low testosterone is especially common in type 2 diabetes and metabolic disease.^[1] Dhindsa and colleagues reported frequent hypogonadotropic hypogonadism in men with type 2 diabetes, which means the testes are often potentially capable of responding but the brain is not signaling properly.^[6] This is a major reason functional hypogonadism is now considered the most common real world form of the condition.

Functional hypogonadism means low testosterone caused by reversible suppression of the hormone axis rather than permanent structural damage to the testes or pituitary. Obesity, insulin resistance, chronic inflammation, and some medications can all push testosterone lower without destroying the system itself.^[1]

A man with obesity, type 2 diabetes, and low testosterone is therefore not “unlucky” three separate times. These conditions feed each other. Visceral fat promotes inflammation and higher aromatase activity. That raises estradiol signaling and suppresses gonadotropin output. Lower testosterone then worsens body composition, physical function, and insulin sensitivity, which feeds the cycle further.

Other high risk populations

High prevalence within cardiovascular disease, COPD, renal disease, and cancer reflects the same broader pattern, namely chronic illness, chronic inflammation, medication burden, and reduced physiologic reserve.^[1]

According to the same guideline literature, low testosterone is overrepresented in men with chronic systemic disease because illness itself can suppress the hypothalamic pituitary gonadal axis, and because the treatments used in these populations often add central or testicular suppression.^[1] This is one reason hypogonadism statistics vary so widely by setting. Community studies, diabetes clinics, obesity clinics, and cardiology populations are not measuring the same baseline risk.

Men in these groups have a higher pretest probability of true androgen deficiency when persistent symptoms are present.

Why aging explains less than many men think

Healthy aging causes only a small gradual testosterone decline, so most clinically important testosterone levels dropping in adult men are driven more by obesity, illness, and medication burden than by age alone.^{[1] [4] [5]}

This is the critical reframe many men never hear. Age matters, but it explains a low percentage of hypogonadism by itself. The steep declines that bring men into clinic usually reflect the biology that accumulates with age, not age as an isolated force.

Healthy aging versus unhealthy aging

The European Male Ageing Study showed that testosterone declines only modestly in healthy older men, and that weight change and lifestyle factors meaningfully modify that trajectory.^[5]

According to EMAS, total testosterone falls gradually in healthy aging, while free testosterone drops somewhat faster. The commonly cited annual changes are small. Roughly 0.4% per year for total testosterone and about 1.3% per year for free testosterone in healthy aging men. Those are not the dramatic drops many symptomatic men experience in practice.^[5]

This distinction helps explain why some men notice major symptoms in midlife while others do not. The key variable is often not chronological age. It is whether obesity, sleep loss, diabetes, cardiovascular disease, medication exposure, and inactivity have accumulated enough to suppress the axis.

What MMAS taught us

Longitudinal data from the Massachusetts Male Aging Study showed that comorbidity and obesity were associated with lower testosterone, while smoking tended to increase testosterone levels.^[4]

The MMAS finding is important because it counters the simplistic idea that testosterone decline in men is just an unavoidable clock. Feldman and colleagues found that men with more illness and higher body weight had lower levels over time, whereas smoking had a relative positive association with testosterone.^[4] That smoking signal does not make smoking protective in any useful clinical sense. It simply illustrates that hormone epidemiology is influenced by behavior and body composition, not age alone.

The smoking paradox may also contribute slightly to generational change, because smoking rates have fallen over time while obesity has risen. But the balance of evidence suggests this contribution is small compared with the much larger negative effect of metabolic disease.

What the generational decline data show

Several cohort analyses suggest a generational testosterone decline, meaning age matched men born later appear to have lower testosterone than men of the same age from earlier birth cohorts.^[3]

Age matched means the comparison is made between men of the same age who were born in different years. That design matters because it separates “getting older” from “being born later.”

The U.S. birth cohort signal

A 2007 Journal of Clinical Endocrinology and Metabolism analysis by Travison and colleagues found that serum testosterone levels declined in American men across successive birth cohorts, even after accounting for age and measured health factors.^[3]

This is the core evidence behind the idea of generational testosterone decline. In practical terms, a man in his 40s today may have a lower testosterone distribution than a 40 year old from an earlier generation, even before obvious disease is diagnosed. That study suggested lower age specific testosterone in later survey years and birth cohorts, beyond aging alone, but the exact population level rate is uncertain.^[3]

That does not mean every later born man will have low testosterone. It means the population curve may be shifting downward, which increases the number of men near symptomatic thresholds.

Parallel signals in male reproductive health

Population concerns about generational decline do not rest on testosterone studies alone. Broader male reproductive data point in the same direction.^[7]

Reports from Israeli military cohorts and Nordic monitoring efforts, including Finnish and Danish datasets, have suggested worsening male reproductive markers over time. The strongest pooled evidence is Levine’s 2017 meta analysis, which found a greater than 50% decline in sperm concentration and total sperm count among men from North America, Europe, Australia, and New Zealand since the 1970s.^[7]

Sperm count is not the same thing as testosterone, so these datasets are not interchangeable. Sperm count trends raise separate concerns about male reproductive health, but they should not be treated as direct evidence of a testosterone decline.

Why low testosterone in young men is rising

Low testosterone in young men is becoming more visible because both true risk factors and testing rates have increased.^[3]

This is why the current discussion can feel confusing. Some of the apparent rise reflects better detection. Some of it appears to reflect a real biologic shift. The most honest reading is that both are happening at once.

Earlier metabolic disease starts earlier hormone problems

Young men now reach adulthood with more metabolic risk than earlier generations, which makes early testosterone suppression more likely. ^[3]

According to the CDC, childhood obesity has risen dramatically over the past several decades, which means many men now enter their 20s already carrying a hormonal environment that favors lower testosterone and higher estradiol signaling. That matters because obesity is the strongest modifiable driver of functional hypogonadism in the real world.^[1]

Chronic sleep deprivation, sedentary behavior, and ultra processed diets amplify that early vulnerability. Men who sleep less, move less, and carry more visceral fat often reach the threshold for symptoms and biochemical deficiency much earlier than their fathers did.

Environmental and medication exposures

Young men today accumulate environmental and medication exposures from childhood onward that may affect hormone signaling, fertility, or both.^{[1] [7]}

Endocrine disrupting chemicals such as BPA, phthalates, and PFAS are a common concern because exposure begins early and is widespread. At the same time, medication exposure starts earlier and lasts longer for many men. SSRIs, finasteride, opioids, glucocorticoids, and prior anabolic steroid or testosterone use can all impair the hormone axis by different mechanisms.^[1]

More testing has also changed the picture

Greater awareness means younger men are now more likely to get tested than they were a decade ago, so part of the apparent increase reflects detection rather than true prevalence.

Direct to consumer hormone marketing, online symptom checkers, and broader discussion of men’s health have lowered the threshold for evaluation. That is not a trivial change. A young man with low libido, fewer morning erections, weight gain, and poor gym recovery is far more likely to search “low testosterone in young men” now than he was in 2005.

But detection alone is not a complete explanation. The birth cohort signal reported by Travison and the long term decline in sperm counts summarized by Levine suggest that at least part of the increase is real.^{[3] [7]}

Why the true prevalence is probably higher than reported

The true prevalence of male hypogonadism is almost certainly higher than published estimates because routine screening is uncommon, diagnostic workups are often incomplete, and some disorders remain hidden for years.^{[1] [8]}

Underdiagnosis starts with missed patterns

Klinefelter syndrome alone illustrates the size of the underdiagnosis problem, because it affects about 1 in 500 to 1,000 men yet fewer than half are ever diagnosed.^[8]

A 2007 clinical review by Bojesen and Gravholt emphasized just how often this common genetic cause of primary hypogonadism goes unrecognized.^[8] If a disorder that common remains hidden in more than half of affected men, it is reasonable to expect broad undercounting across hypogonadism as a whole.

Many primary care settings still do not recognize the pattern that should trigger evaluation. Libido change, erectile dysfunction, reduced morning erections, increasing waist circumference, lower exercise tolerance, and persistent fatigue are often addressed separately instead of as one endocrine picture. Insurance barriers and stigma around sexual symptoms further reduce detection.

Incomplete testing is another major reason prevalence is underestimated. A proper evaluation requires morning testing and classification of the axis. LH and FSH must be measured alongside testosterone. Without them, clinicians cannot tell whether the problem is primary or secondary hypogonadism, and they cannot choose the correct treatment path.^[1] For the next step after prevalence data, see The complete low testosterone testing guide: what to order, when to test, and how to read results and Functional vs organic hypogonadism: is your low T reversible?.

COVID 19 and the population data gap

COVID 19 exposed how clinically important low testosterone may be, but it also highlighted how incomplete our surveillance remains.^[9]

Rastrelli and colleagues found that men with lower testosterone during SARS CoV 2 pneumonia had markedly worse outcomes, with roughly a fivefold increase in risk for ICU transfer or death in one influential cohort.^[9] Some observational studies explored whether prior testosterone therapy was associated with outcomes, but these data are not sufficient to infer benefit.

The geographic picture is also incomplete. Denmark and Finland have stronger national reproductive health tracking than the United States, while the U.S., despite having the largest men’s health market, has no equivalent national testosterone surveillance program. Most major cohort studies also skew toward White Western populations. Reported racial and ethnic differences in testosterone are complicated by differences in SHBG, body composition, and access to care, which means today’s hypogonadism statistics are informative but not fully representative.

In other words, when men ask whether testosterone levels are dropping or whether low testosterone prevalence is rising, the honest answer is that the trend is probably real, but the exact magnitude remains hard to measure because the population monitoring system is still incomplete.

Myth vs fact

Myth: Aging alone causes most low testosterone.

Fact: Healthy aging causes only a small gradual decline in testosterone. Obesity, diabetes, weight gain, chronic disease, and medications explain much more of the real world burden.^{[4] [5]}

Myth: Low testosterone in young men is mostly internet hype.

Fact: More testing has increased detection, but cohort data show age matched later birth cohorts have lower testosterone, and broader male reproductive data show long term declines in sperm counts as well.^{[3] [7]}

Myth: A single low testosterone number proves the diagnosis.

Fact: Male hypogonadism is a clinical syndrome that requires persistent symptoms plus biochemical evidence, ideally confirmed on repeated morning testing, and LH with FSH must be checked to classify the cause.^{[1] [2]}

Myth: Obesity, diabetes, and low testosterone are separate problems.

Fact: These conditions commonly reinforce one another. Low testosterone is especially common in type 2 diabetes and metabolic syndrome, and the relationship is bidirectional rather than coincidental.^{[1] [6]}

Myth: The rise is only because men get tested more often.

Fact: Increased testing clearly matters, but it does not fully explain the trend. Birth cohort analyses, earlier obesity, wider medication exposure, and long term reproductive health data all suggest a true underlying shift as well.^{[3] [7]}

Bottom line

Low testosterone is common enough to matter, underdiagnosed enough to be missed, and increasingly relevant in younger men because the main drivers now start earlier in life. Published prevalence of about 2.1% to 5.7% in men aged 40 to 79 almost certainly understates the true burden, and the best evidence suggests that both detection and a real generational shift are contributing to today’s concern about testosterone levels dropping. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers a thorough diagnostic workup across the U.S., including advanced testing with Total Testosterone by LC MS/MS, Free Testosterone by Equilibrium Dialysis with LC MS/MS, LH, FSH, Estradiol, CBC, Comprehensive Metabolic Panel, Vitamin D, PSA when age appropriate, and other clinically indicated markers, or a review of existing lab results including uploaded outside testing. Based on those results, licensed providers build individualized plans, with Enclomiphene as first line for appropriate secondary or functional hypogonadism, the Enclomiphene plus Tadalafil combination tablet when erection or urinary symptoms are also present, and ongoing monitoring with protocol adjustments over time.

References

1. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. European urology. 2025;88:76-102. PMID: 40340108
2. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. The New England journal of medicine. 2010;363:123-35. PMID: 20554979
3. Travison TG, Araujo AB, O’Donnell AB, et al. A population-level decline in serum testosterone levels in American men. The Journal of clinical endocrinology and metabolism. 2007;92:196-202. PMID: 17062768
4. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. The Journal of clinical endocrinology and metabolism. 2002;87:589-98. PMID: 11836290
5. Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European journal of endocrinology. 2013;168:445-55. PMID: 23425925
6. Basaria S. Male hypogonadism. Lancet (London, England). 2014;383:1250-63. PMID: 24119423
7. Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Human reproduction update. 2017;23:646-659. PMID: 28981654
8. Lanfranco F, Kamischke A, Zitzmann M, et al. Klinefelter’s syndrome. Lancet (London, England). ;364:273-83. PMID: 15262106
9. Groti Antonic K, Antonic B, Caliber M, et al. Men, testosterone and Covid-19. Clinical endocrinology. 2024;100:56-65. PMID: 37501254